Zacks: Analysts Expect Pieris Pharmaceuticals Inc (PIRS) to Post -$0.16 Earnings Per Share

Share on StockTwits

Brokerages expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to post earnings of ($0.16) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.12). Pieris Pharmaceuticals reported earnings per share of $0.17 during the same quarter last year, which suggests a negative year-over-year growth rate of 194.1%. The firm is expected to report its next earnings report on Friday, March 8th.

On average, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.45) per share for the current year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the business will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.07) to ($0.62). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.16 million. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%.

A number of analysts have recently issued reports on PIRS shares. BidaskClub upgraded shares of Pieris Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 26th. Cowen restated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday, November 11th. ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. Finally, HC Wainwright set a $12.00 target price on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $10.00.

In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy acquired 5,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was acquired at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.07% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its stake in Pieris Pharmaceuticals by 49.1% in the 2nd quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after purchasing an additional 884,348 shares in the last quarter. Acadian Asset Management LLC raised its stake in Pieris Pharmaceuticals by 2.0% in the 3rd quarter. Acadian Asset Management LLC now owns 2,167,227 shares of the biotechnology company’s stock worth $12,136,000 after purchasing an additional 42,354 shares in the last quarter. Aquilo Capital Management LLC acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth about $10,013,000. Prosight Management LP increased its holdings in Pieris Pharmaceuticals by 22.2% in the 3rd quarter. Prosight Management LP now owns 1,661,940 shares of the biotechnology company’s stock valued at $9,307,000 after buying an additional 301,940 shares during the period. Finally, Sphera Funds Management LTD. increased its holdings in Pieris Pharmaceuticals by 7.4% in the 3rd quarter. Sphera Funds Management LTD. now owns 904,686 shares of the biotechnology company’s stock valued at $5,066,000 after buying an additional 62,054 shares during the period. Institutional investors and hedge funds own 65.36% of the company’s stock.

Shares of NASDAQ PIRS remained flat at $$3.51 during mid-day trading on Monday. 428,334 shares of the stock were exchanged, compared to its average volume of 569,235. The firm has a market cap of $190.07 million, a PE ratio of -8.78 and a beta of 1.88. Pieris Pharmaceuticals has a one year low of $3.04 and a one year high of $9.75.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.